Vivani Medical Unveils Positive Preclinical Data for NPM-115 and NPM-139, Shifting Focus to Obesity Portfolio

Photo of author
Written By Joel Gbolade

Vivani Medical, Inc. (Nasdaq: VANI) has made significant strides in its preclinical research endeavors, unveiling positive data for NPM-115 and NPM-139, marking a strategic shift towards prioritizing its obesity portfolio. 

The company’s innovative approach to drug delivery through miniature, long-term implants holds promise for revolutionizing chronic weight management and enhancing treatment adherence. 

This announcement underscores Vivani’s commitment to addressing unmet medical needs and advancing therapeutic options for patients facing obesity and related metabolic disorders.

Key Insights

The disclosure of semaglutide as the active pharmaceutical ingredient in NPM-139, coupled with promising preclinical results for NPM-115, signals a strategic realignment towards prioritizing the company’s obesity implants. 

Credits: DepositPhotos

By leveraging its proprietary NanoPortal™ platform, Vivani aims to ensure medication adherence and improve treatment tolerability through smooth and steady delivery of GLP-1 therapy. 

The decision to focus on obesity implants aligns with emerging data suggesting the potential for high-dose GLP-1 products to improve health outcomes for obese and overweight individuals.

Read More: Verve Therapeutics Inc (VERV) Charts Impressive Progress and Financials for Q4 and Full Year 2023

CEO Highlights Strategic Shift 

Vivani President and CEO, Dr. Adam Mendelsohn, highlighted the company’s strategic shift, emphasizing the urgent medical need and market demand for innovative obesity treatments. 

The compelling weight loss data from NPM-115, combined with the potential benefits of once-yearly dosing with NPM-139, underscores the transformative potential of Vivani’s implant technology in advancing GLP-1 therapy. 

With the obesity market ripe for innovation, Vivani is poised to capitalize on its novel approach to drug delivery and contribute to improved patient outcomes.

Preclinical Data Insights

In preclinical studies involving high-fat diet-induced obese mice, NPM-115 demonstrated significant weight loss effects, comparable to those observed with semaglutide injections (Ozempic/Wegovy). 

These findings underscore the efficacy of Vivani’s implant technology in delivering GLP-1 therapy and its potential to achieve meaningful weight reduction in animal models. 

Additionally, preclinical data for NPM-119, a GLP-1 implant for the treatment of type 2 diabetes, exhibited promising results, further validating the durability and effectiveness of Vivani’s implant technology in promoting weight loss and metabolic control.

Also Read: Viking Therapeutics Announces Plans for Public Offering of Common Stock

Maximizing Therapeutic Potential  

Dr. Mendelsohn highlighted the potential of long-term GLP-1 implants to address limitations associated with existing treatment modalities, such as adherence and dosing challenges. 

Vivani’s implants offer a solution by providing continuous dosing over extended intervals, thereby maximizing the therapeutic potential of GLP-1 therapy. 

The company’s commitment to advancing NPM-115, NPM-139, and its broader portfolio underscores its dedication to improving patient outcomes and addressing the growing burden of obesity and related metabolic disorders.

Commitment to Innovation and Growth  

Vivani Medical’s strategic shift towards prioritizing its obesity portfolio reflects its commitment to innovation and addressing unmet medical needs in the field of chronic weight management. 

Credits: DepositPhotos

With promising preclinical data supporting the efficacy of its implant technology and the disclosure of semaglutide as the active ingredient in NPM-139, Vivani is poised to make significant contributions to the treatment landscape for obesity and related metabolic disorders. 

As the company advances its implant technology and prepares for clinical development, it remains focused on delivering transformative therapies that enhance patient outcomes and improve quality of life.

Read Next: RAPT Therapeutics Stock Falls off a Cliff, but why?



You should read and understand this disclaimer in its entirety before joining or viewing the website or email/blog list of (the “Publisher”). The information (collectively the “Advertisement”) disseminated by email, text or other method by the Publisher including this publication is a paid commercial advertisement and should not be relied upon for making an investment decision or any other purpose. The Publisher is engaged in the business of marketing and advertising the securities of publicly traded companies in exchange for compensation. The track record, gains, upside, and/or losses mentioned in the Advertisement, if any, should not be considered as true or accurate or be the basis for an investment. The Publisher does not verify the accuracy or completeness of any information included in the Advertisement. While the Publisher does not charge for the SMS service, standard carrier message and data rates may apply. To unsubscribe from receiving promotional text messages to your phone sent via an autodialer, using your phone reply to the sender’s phone number with the word STOP or HELP for help.

The Advertisement is not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the states or other jurisdictions in which the security is eligible for sale. The Advertisement is not a disclosure document. The Advertisement is only a favorable snapshot of unverified information about the advertised company. An investor considering purchasing the securities, should always do so only with the assistance of his legal, tax and investment advisors. Investors should review with his or her investment advisor, tax advisor or attorney, if and to the extent available, any information concerning a potential investment at the web sites of the U.S. Securities and Exchange Commission (the "SEC") at; the Financial Industry Regulatory Authority (the "FINRA") at, and relevant State Securities Administrator website and the OTC Markets website at The Publisher cautions investors to read the SEC advisory to investors concerning Internet Stock Fraud at, as well as related information published by the FINRA on how to invest carefully. Investors are responsible for verifying all information in the Advertisement. As an advertiser, we do not verify any information we publish. The Advertisement should not be considered true or complete.

The Publisher does not offer investment advice or analysis, and the Publisher further urges you to consult your own independent tax, business, financial and investment advisors concerning any investment you make in securities particularly those quoted on the OTC Markets. Investing in securities is highly speculative and carries an extremely high degree of risk. You could lose your entire investment if you invest in any company mentioned in the Advertisement. You acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser and we are not qualified to act as such. You acknowledge that you will consult with your own independent, tax, financial and/or legal advisers regarding any decisions as to any company mentioned here. We have not determined if the Advertisement is accurate, correct or truthful. The Advertisement is compiled from publicly available information, which include, but are not limited to, no cost online research, magazines, newspapers, reports filed with the SEC or information furnished by way of press releases. Because all information relied upon by us in preparing an advertisement about an issuer comes from a public source, it is not reliable, and you should not assume it is accurate or complete.

By your subscription to our profiles, the viewing of this profile and/or use of our website, you have agreed and acknowledged the terms of our full disclaimer and privacy policy which can be viewed at the following link: and

By accepting the Advertisement, you agree and acknowledge that any hyperlinks to the website of (1) a client company, (2) the party issuing or preparing the information for the company, or (3) other information contained in the Advertisement is provided only for your reference and convenience. The advertiser is not responsible for the accuracy or reliability of these external sites, nor is it responsible for the content, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated report/release or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on the Publisher, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink.